GID BIO seeks up to USD 25m to support cellular medicine platform, CEO says

Mergermarket is the leading provider of forward-looking M&A intelligence and data to investment banks, private equity firms, law firms, accounting firms, corporates and other M&A professionals around the world. WWW.MERGERMARKET.COM   JANUARY 16, 2020 BY DEB BALSHEM   GID BIO, a privately held cellular medicine company, is looking to raise between USD 20m and USD […]

Read More   ►

An interview with William Cimino, PhD, CEO GID BIO, International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France

GID BIO CEO William Cimino, PhD sat down with SmartTRAK, BioMedGPS Senior Analyst, Regenerative Medicine at the International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France. Click here to listen to the full interview. […]

Read More   ►

6 Orthobiologic Companies Move Clinical Trials Forward

Multiple orthobiologic companies have engaged in clinical trials in 2019, seeking to demonstrate the efficacy of their cell-based products….   GID BIO completed a multi-site, randomized, placebo-controlled Phase IIb clinical trial with an FDA-approved study design using autologous stromal cells in the treatment of knee osteoarthritis (OA), successfully meeting endpoints and two-year safety results…   Read more via BONEZONE. […]

Read More   ►

GID BIO Completes Trial of Stromal Cells to Treat Knee OA

GID BIO completed a pivotal Phase IIb clinical trial with an FDA-approved study design using autologous stromal cells in the treatment of knee osteoarthritis (OA), successfully meeting endpoints and two-year safety results…   Read more via ORTHOWORLD: https://www.orthoworld.com/index.php/publications/orthoflash/gid-bio-completes-trial-of-stromal-cells-to-treat-knee-oa […]

Read More   ►